Can Diabetes Medications Reduce Alzheimer’s Risk? What the Research Shows

The Link Between Type 2 Diabetes and Alzheimer’s Disease

The connection between type 2 diabetes and Alzheimer’s disease is so strong that some researchers have proposed calling Alzheimer’s “type 3 diabetes.” Both conditions involve insulin resistance, chronic inflammation, and metabolic dysfunction — and having type 2 diabetes roughly doubles the risk of developing Alzheimer’s disease.

This overlap has raised an important and exciting research question: could the medications we already use to treat type 2 diabetes also protect the brain against cognitive decline?

GLP-1 Receptor Agonists: The Most Promising Evidence

GLP-1 receptor agonists — including semaglutide (Ozempic, Wegovy), liraglutide (Victoza), and dulaglutide (Trulicity) — have attracted the most attention for potential brain-protective effects.

GLP-1 receptors are present throughout the brain, particularly in regions involved in memory and cognition. Animal studies have shown that GLP-1 agonists reduce amyloid plaque accumulation, decrease neuroinflammation, and improve cognitive performance. Human observational data has been similarly encouraging:

• A 2023 study published in JAMA Neurology found that people with type 2 diabetes taking GLP-1 agonists had a significantly lower incidence of Alzheimer’s disease compared to those on other diabetes medications.
• Liraglutide showed neuroprotective effects in early-phase clinical trials, slowing markers of neurodegeneration in patients with mild Alzheimer’s.
• Semaglutide is currently being studied in large Phase III trials specifically for Alzheimer’s disease (the EVOKE trials), representing one of the most anticipated areas of dementia research.

The National Institute on Aging is actively funding research into GLP-1 therapies for Alzheimer’s prevention and treatment.

Metformin: Long-Used, Now Being Studied for the Brain

Metformin is the most widely prescribed medication for type 2 diabetes, and evidence suggests it may also have cognitive benefits. Several large observational studies have found that long-term metformin users have a lower incidence of dementia compared to those who never took it.

The proposed mechanisms include:

• Reduction of chronic inflammation in the brain and body
• Activation of AMPK, a cellular energy sensor that promotes healthy cell function and may clear damaged proteins
• Improved insulin sensitivity in the brain
• Reduced oxidative stress

The ongoing TAME trial (Targeting Aging with Metformin) is investigating metformin’s ability to slow aging and reduce age-related diseases, including dementia. Results are expected in the coming years and may reshape how metformin is prescribed.

SGLT-2 Inhibitors: Emerging Brain Health Data

SGLT-2 inhibitors — including empagliflozin (Jardiance), dapagliflozin (Farxiga), and canagliflozin (Invokana) — have already demonstrated remarkable cardiovascular and kidney-protective benefits. Emerging data also suggests possible cognitive benefits.

These medications reduce inflammation and oxidative stress at the cellular level and may protect brain blood vessels from damage. Real-world registry studies have shown lower rates of dementia among SGLT-2 inhibitor users, though randomized trial evidence specific to dementia is still forthcoming.

Insulin Sensitizers (Thiazolidinediones)

Pioglitazone (Actos) and other thiazolidinediones improve insulin sensitivity and have demonstrated anti-inflammatory properties. Some observational data has suggested lower dementia rates in people who used these medications, although their use has declined due to side effects including fluid retention and fracture risk.

Research into their possible role in Alzheimer’s prevention continues.

What This Means for Patients Right Now

The evidence is promising but still evolving. Here is what it means practically:

• Do not change your medications based on this research alone. Alzheimer’s prevention is not yet an approved indication for any diabetes drug, and medication decisions should always involve your doctor.
• If you are choosing between equally effective diabetes therapies, your doctor may consider cognitive risk as one factor in the decision — particularly if you have a family history of dementia or other risk factors.
• Prioritize blood sugar control overall. Regardless of which medication you take, maintaining good glycemic control protects both the cardiovascular system and the brain.
• Lifestyle factors still dominate. Exercise, diet, sleep, and cardiovascular risk management remain the strongest proven tools for brain protection in people with type 2 diabetes.

The Bottom Line

Multiple diabetes medications — particularly GLP-1 receptor agonists, metformin, and SGLT-2 inhibitors — show genuine promise in reducing Alzheimer’s risk and cognitive decline. The biological rationale is sound, the observational data is encouraging, and major clinical trials are underway. While no definitive recommendations can yet be made for prescribing these drugs specifically to prevent dementia, the intersection of metabolic and brain health is one of the most exciting frontiers in medicine today.

This article is for informational purposes only and does not constitute medical advice. Please consult a qualified healthcare provider about your personal health situation and treatment options.

Related Reading

• Type 2 Diabetes Complications: What You Need to Know
• Best Treatment Options for Type 2 Diabetes
• Type 2 Diabetes: Symptoms, Causes, and Management

keithsurveys2@gmail.com

Keith Williams is the creator of ABCs of A1C, an educational resource focused on blood sugar control and Type 2 diabetes awareness. His work focuses on translating complex metabolic and diabetes research into practical lifestyle information that readers can understand and apply in daily life.

See Full Bio